Skip to content

Cumberland Pharmaceuticals CPIX Free cash flow yield

Free cash flow yield at other companies

Baxter International logo
Baxter InternationalBAX
3.4%-0.5pp
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-3.1%
RFL
Rafael Holdings, Inc.RFL
-31.9%
Opko Health logo
Opko HealthOPK
-20.1%+1.9pp
Organon logo
OrganonOGN
43.8%+23.6pp
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
-3.1%

Other financials

Income statement

See full
Revenue$9.1M-22.0%
Gross profit$7.2M-30.0%
Operating income-$3.1M-342%
Net income-$3.3M-362%
EPS (diluted)-$0.22-375%

Balance sheet

See full
Cash & equivalents$11.0M-27.1%
Total debt$4.8M-7.1%
Total equity$21.6M-24.5%
Total assets$71.0M+1.5%

Cash flow

See full
Operating cash flow$387.0K-90.1%
CapEx--100%
Free cash flow$387.0K-89.9%

Valuation

See full
Market cap$97.09M+142%
Enterprise value$90.91M+212%
P/S2.3×+1.4×

Profitability

See full
Gross margin82.9%-1.4pp
Operating margin-17.2%-125pp
Net margin-17.6%-103pp
FCF margin3.3%

Returns & leverage

See full
Return on equity-29.4%-86.3pp
Debt / equity0.2×0.0×
Current ratio-0.3×

Where this comes from

Calculated from Cumberland Pharmaceuticals’s reported figures.

Based on trailing twelve months.

The official record: Cumberland Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cumberland Pharmaceuticals's free cash flow yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cumberland Pharmaceuticals's free cash flow yield?
Cumberland Pharmaceuticals (CPIX) reported free cash flow yield of 2.8% in Q1 2026.
What is the long-term trend for Cumberland Pharmaceuticals's free cash flow yield?
Over 4 years (2020 to 2025), Cumberland Pharmaceuticals's free cash flow yield has grown at a -9.2% compound annual growth rate (CAGR), from 11.9% to 8.1%.
What does free cash flow yield mean?
Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.